Perspectum Stock

perspectum.comHealthcare / Digital HealthFounded: 2012

Perspectum is a biotech firm serving healthcare providers with imaging services to help them make diagnostics and treatment decisions for their patients. Perspectum’s imaging technology is patented and contains a one scan approach able to produce a three-dimensional return. The private company’s devices are fully integrated into any healthcare setting and can be used by physicians, imaging providers, and pharma solutions to provide full treatment of ailments such as liver disease, diabetes, and cancer.

Register To Buy and Sell Shares

For more details on financing and valuation for Perspectum, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Perspectum’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Perspectum.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Perspectum investors also invested in these private companies

Oppenheimer & Co.
Puhua Capital
University of Oxford
BlueCross BlueShield Venture Partners
Oxford Science Enterprises
HealthQuest Capital
Oxford University Innovation

Team

Management Team

Dr. Rajarshi Banerjee
Chief Executive Officer
Amanda Chin
VP Corporate Development
Dr. Keri Hildick
Chief Strategy Officer
Dr. Cat Kelly
Chief Informatics Officer
Debbie Ledet
Chief Access Officer
Dr. Rexford Newbould
Chief Operating Officer
Dr. Matthew Robson
Chief Technical Officer

Board Members

Professor Sir Michael Brady
Chairman
George Embiricos
Non-Executive Director
Dr. Elizabeth Fagan
Non-Executive Director
Thomas Hawes
Non-Executive Director
Garheng Kong
Observer
Kevin Lim
Non-Executive Director
Dr. Michael Rosenblatt
Non-Executive Director
Dr. Emir Sandhu
Non-Executive Director
Chun Tan
Non-Executive Director

Perspectum’s stock FAQs

plusminus

Can you buy Perspectum’s stock?

Perspectum is not publicly traded on NYSE or NASDAQ in the U.S. To buy Perspectum’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Perspectum’s stock?

Yes, you can sell stock of a private company like Perspectum. Forge can help you sell your Perspectum stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus

What is Perspectum’s stock price?

Perspectum is a privately held company and therefore does not have a public stock price. However, you may access Perspectum’s private market stock price with Forge Data.
plusminus

What is Perspectum’s stock ticker symbol?

Perspectum does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Perspectum Completes $36 Million First Close of Series C Funding Led by Oppenheimer Holdings

Perspectum, a precision health company which develops medical imaging tools to improve the diagnoses of metabolic diseases and cancer, has completed the first close of its Series C funding round.
Updated on: Jul 14, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.